

BMJ Open High-risk factors for adverse pregnancy outcomes in systemic lupus erythaematosus: a retrospective study of a Chinese population

Meng Jiang,^{1,2} Yanling Chang,^{1,2} You Wang,^{1,2} Qiong Fu ,^{3,4} Sihan Lin,^{1,2} Jiayue Wu ,^{1,2} Wen Di^{1,2,5}

To cite: Jiang M, Chang Y, Wang Y, *et al*. High-risk factors for adverse pregnancy outcomes in systemic lupus erythaematosus: a retrospective study of a Chinese population. *BMJ Open* 2021;**11**:e049807. doi:10.1136/bmjopen-2021-049807

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-049807>).

MJ and YC contributed equally.

MJ and YC are joint first authors.

Received 04 February 2021

Accepted 20 October 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Jiayue Wu;
janet_wu_jiayue@163.com and
Dr Wen Di;
diwen163@163.com

ABSTRACT

Objective To clarify high-risk factors for adverse pregnancy outcomes (APOs) in systemic lupus erythaematosus (SLE).

Design A retrospective chart review study.

Setting Data were collected in a tertiary medical centre, Shanghai, China, from November 2010 to December 2018.

Participants A total of 513 pregnancies with SLE were retrospectively analysed. Twenty-seven patients who underwent artificial abortions due to personal reasons were excluded.

Primary outcome measures APOs were primary outcomes, including foetal loss, premature birth, small for gestational age (SGA), asphyxia neonatorum, composite foetal APOs and hypertensive disorders of pregnancy (HDP). Multivariable logistic regression and Spearman correlation analysis were performed to determine the risk factors for APOs in SLE.

Results Risk factors for foetal loss included prepregnancy hypertension, hypocomplementaemia-C3, anticardiolipin antibodies-IgM positivity and disease flares during pregnancy. Risk factors for premature birth included disease flares, use of immunosuppressive agents and HDP. Moreover, twin pregnancy, disease flares and HDP were risk factors for SGA, and prepregnancy hypertension was an independent risk factor for asphyxia neonatorum. Independent risk factors for composite foetal APOs included twin pregnancy, prepregnancy hypertension, disease flares during pregnancy, HDP, hypocomplementaemia-C3 and the use of immunosuppressive agents. Risk factors for SLE complicated with HDP included prepregnancy hypertension, renal disorders and thrombocytopenia. Conversely, the use of aspirin was a protective factor against foetal loss and premature birth. The ds-DNA value had a low diagnostic value for APOs, whereas the extent of complement reduction may predict the incidence of composite foetal APOs and foetal loss. Proteinuria occurring in the first 20 gestational weeks may lead to APOs.

Conclusion Established risk factors for each APO were identified in this study. Indicators with more predictive significance have been screened out from conventional indicators, which may help clinicians predict the pregnancy outcome of patients with SLE more accurately and minimise the incidence of APOs.

Strengths and limitations of this study

- A comprehensive analysis was performed of the most important risk factors for the main maternal and foetal adverse pregnancy outcomes (APOs) caused by placental dysfunction in systemic lupus erythaematosus (SLE) pregnancy with a large sample size.
- The study demonstrated that the ds-DNA value had a low diagnostic value for APOs, whereas the extent of complement decrease, especially C3, may predict the incidence of composite foetal APOs, especially foetal loss.
- The study contributes to a better counselling of obstetric surveillance in SLE pregnancy.
- As a retrospective study, inherent information bias was present.

INTRODUCTION

Systemic lupus erythaematosus (SLE) is an autoimmune disease involving multiple organs and autoantibodies. Nearly 90% of females with SLE are of reproductive age.¹ Previous epidemiological studies have demonstrated that the prevalence and incidence rates of patients with SLE among Asians are approximately 2–3 times higher than those among Caucasians. China has a higher prevalence of SLE than many other countries, especially among women (estimated to be more than 100 per 100 000 persons). Based on an estimated Chinese population of 1.3 billion published in 2009, the number of lupus patients in China could reach 520 000–910 000, which would be the largest cluster of cases in the world.² To tolerate the paternal antigens expressed in foetal cells or tissues, the maternal immune system may undergo adaptive changes during pregnancy, which can stimulate the autoimmune response and lead to SLE flares. The flare rate in pregnancy has been reported

to range from 13% to 68%, accompanied by irreversible organ damage and adverse pregnancy outcomes (APOs).³ Although diagnostic and therapeutic strategies for SLE have greatly improved, SLE in pregnancy is still a high risk factor due to frequent complications, including preeclampsia (PE), small for gestational age (SGA), foetal loss and premature birth.^{4,5}

Prepregnancy counselling and perinatal care are essential for the prevention of APOs in the SLE population. Indeed, potential clinical risk factors and serological predictors of adverse outcomes in SLE pregnancies have been widely studied in recent decades.^{6–13} Nevertheless, there is no consensus regarding predictors for each APO, and most risk factors are presented as categorical variables. Given the different incidences of SLE in various countries and the limitation of methodology consistency, there is a need for a concise and evidence-based list of indicators to estimate SLE pregnancy risk. In addition, it remains unknown whether the extent of the abnormality of disease activity indexes for SLE, such as ds-DNA, complement and proteinuria, can accurately predict pregnancy outcomes. Furthermore, there are few studies involving large samples. Ren Ji Hospital has treated a leading number of SLE pregnancies in China, which provided our study with a rare large single-centre sample. Here, we evaluated 513 pregnant women and analysed high-risk factors for adverse SLE maternal and foetal outcomes to strengthen management and improve SLE pregnancy outcomes.

METHODS

Patient population

This was a retrospective study performed at Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. The medical records of all pregnant patients with SLE (meeting ≥ 4 of the revised American College of Rheumatology criteria¹⁴) between November 2010 and December 2018 were reviewed. The total number of deliveries in our hospital during the study period reached 24 859, with SLE pregnancies accounted for 2.2%. Twenty-seven patients who underwent artificial abortions due to personal reasons rather than therapeutic reasons were excluded. Rheumatologists diagnosed and obstetricians jointly managed SLE pregnant women.

Variables of interest

Clinical and laboratory information was recorded from the first antenatal care records (16–20 gestational weeks). Baseline maternal information included age, obstetric history, duration of SLE, previous manifestations of SLE (including renal disorders, mucocutaneous disorders, haematological disorders, neurological disorders, arthritis and serositis) and medication use. Comorbidities included prepregnancy hypertension and diabetes. Laboratory data collected included 24-hour urinary protein, antinuclear antibodies, complement 3 (C3), complement 4 (C4), ds-DNA and antiphospholipid

antibody (aPL) results. aPL included IgG/IgM anticardiolipin antibodies (aCLs) and anti- β -2-glycoprotein I antibodies (anti- β 2GPI); only titres of aCLs, β 2GPI IgG, IgM ≥ 40 GPL or MPL units were considered positive. All laboratory tests were performed using standardised methods. Each pregnancy was recorded as a separate observation. Pregnancy outcomes were also evaluated, including delivery mode, foetal survival, Apgar score and foetal birth weight.

Patient and public involvement

Patients and the public were not involved in the design and conception of the study and there are no plans to disseminate the results to patients.

Definitions

Foetal APOs included one or more of the following: (1) foetal loss—spontaneous abortion (referring to termination before 28 weeks of pregnancy with foetal weight less than 1000 g), therapeutic abortion (iatrogenic abortion caused by a lupus flare or obstetric complications threatening the life of the mother), stillbirth (any baby born without signs of life at ≥ 28 completed weeks of gestation), and neonatal death (death of a liveborn baby within 28 days after birth)¹⁵; (2) premature birth—delivery prior to 37 weeks of gestation¹⁶; (3) SGA—birth weight below the 10th percentile according to gestational week at delivery and foetal sex¹⁷; and (4) asphyxia neonatorum—Apgar score of < 7 at 1 and/or 5 min after birth.¹⁸ Composite foetal APOs were defined as the occurrence of any adverse outcomes, including foetal loss, premature birth, SGA and asphyxia neonatorum.

Hypertensive disorders of pregnancy (HDPs) were categorised into three types in this study. (1) Gestational hypertension (GH): new-onset blood pressure $\geq 140/90$ mm Hg without proteinuria after 20 weeks of gestation. (2) PE: the first incidence of systolic blood pressure (SBP) ≥ 140 mm Hg and/or diastolic blood pressure (DBP) ≥ 90 mm Hg after 20 weeks of gestation plus one of the following criteria, protein loss of 300 mg or more in a 24-hour urine specimen or maternal organic dysfunction, such as loss of renal function, hepatic dysfunction, neurological complications (altered mental state, blindness, scotomas, visual blurring), haematological complications (thrombocytopenia, haemolysis) or intrauterine growth restriction; PE can also overlap with other hypertensive states, such as prepregnancy hypertension preceding pregnancy or identified before 20 weeks. (3) Eclampsia: new-onset generalised seizures in a woman with PE.¹⁹

A disease flare during pregnancy was defined as a new or worsened presence of arthritis, malar rash, vasculitis, oral or nasal ulcers, serositis, neurological manifestations, haematological disorders, fever attributable to SLE, the addition of immunosuppressive medications or hydroxychloroquine, or an increase in prednisone ≥ 0.5 mg/kg/day. Additionally, new-onset SLE during pregnancy was included.²⁰

Statistical analyses

Continuous variables were analysed using analysis of variance tests when the distributions were normal or Kruskal-Wallis H tests when the distributions were not normal, and the results are presented as the mean±SD or as the frequency. Categorical variables were analysed using χ^2 or Fisher's exact probability tests as appropriate. Multivariable and stepwise regression ($p < 0.05$ for forward steps and $p < 0.10$ for backward steps) was performed by selecting variables with a p value < 0.05 in the univariate analysis. For categorical variables, univariate ORs and corresponding 95% CIs were computed. Spearman tests were employed to determine correlations between variables. The area under the receiver operating characteristic (ROC) curve (AUC) was used to assess discrimination of continuous variables with a p value < 0.05 in the Spearman test and to obtain the critical cut-off value. All tests were two-tailed, and $p < 0.05$ was considered statistically significant. All analyses were performed using SPSS V.25.0.

RESULTS

Population characteristics

A total of 513 pregnancies in 484 patients with SLE were recorded at Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, between November 2010 and December 2018. Of these patients, 456 (94.2%) had 1 pregnancy within the study period, 27 (5.6%) had 2 pregnancies and 1 (0.2%) had three pregnancies. Through retrieval by case diagnosis, 41 cases of antiphospholipid antibody syndrome were identified among patients with SLE. The mean age at conception was 29.7 ± 4.0 years (range, 20–40 years). The average duration of SLE before pregnancy was 6.6 ± 4.3 years (range, 1–18 years). There were 238 cases (46.4%) of primipara, 505 cases (98.4%) of singleton pregnancy and 8 cases (1.6%) of twin pregnancy. Twenty-one patients (4.1%) had prepregnancy hypertension. Almost 96% of the patients (495 cases) were in the SLE remission stage for more than 6 months prior to conception. Eighty-two of the patients (16%) had a disease flare before 20 weeks of gestation. A total of 501 patients (97.7%) used prednisone, 405 (78.9%) took hydroxychloroquine and 45 (8.8%) received immunosuppressive medications (such as azathioprine, tacrolimus and cyclosporine A). Of the patients, 398 (77.6%) used aspirin, and 138 (26.9%) received low-molecular-weight heparin.

Foetal outcomes

A total of 444 pregnancies (86.5%) resulted in live births. The average gestation days for the live births were 260.10 ± 15.06 days (range, 201–282 days), and the average foetal weight was 2797.96 ± 563.951 g (range, 940–4370 g). In total, 128 (24.9%) premature births were recorded, and there was no significant difference in the premature birth rate between twins and singletons ($\chi^2 = 115.28$, $p = 0.09$).

There were 11 cases (2.1%) with an Apgar score < 7 at 1 min after birth. Only one newborn had Apgar scores < 7 at 5 and 10 min after rescue and ultimately died due to oedema. In all cases of asphyxia neonatorum, there was no evidence of cardiac malformations based on B-ultrasound during pregnancy. The overall foetal loss rate was 13.6% (70 cases), and the SGA rate was 23.4% (120 cases). There were 236 cases (46.0%) with composite foetal APOs.

Maternal outcomes

In this study, 145 patients (28.3%) experienced disease flares during pregnancy. Among 513 pregnancies, 90 patients (17.5%) eventually developed HDP, 16 patients (3.1%) had GH, 74 patients (14.4%) had PE and 2 developed eclampsia (0.4%). All patients with disease flares and HDPs received timely diagnosis and treatment. One maternal death occurred in a patient with lupus that remained active without evaluation by the rheumatologist or obstetrician after conception. This patient was 30 years old and dramatically deteriorated with pulmonary haemorrhage, and multiple organ failure developed 15 days after iatrogenic abortion.

Predictors of adverse foetal and maternal outcomes

Table 1 provides a comparison of clinical events as well as laboratory parameters in patients with or without composite foetal APOs. Multivariable analysis revealed that multiple pregnancies, prepregnancy hypertension, disease flares during pregnancy, HDP, hypocomplementaemia-C3 and the use of immunosuppressive agents were independent predictors of composite foetal APOs (table 2).

Univariate analysis of foetal APOs is shown in online supplemental table 1. Multivariable analysis revealed that prepregnancy hypertension, hypocomplementaemia-C3, aCL-IgM positivity and disease flares during pregnancy were risk factors for foetal loss. Disease flares during pregnancy, HDPs and the use of immunosuppressive agents were responsible for premature birth, and multiple pregnancies, disease flares during pregnancy and HDPs were independent predictors of SGA. Moreover, the occurrence of asphyxia neonatorum correlated significantly only with prepregnancy hypertension (table 3).

The maternal characteristics significantly associated with HDPs in the univariate analysis are shown in table 4. In the multivariable analysis, prepregnancy hypertension (OR=9.03), renal disorders (OR=2.71) and thrombocytopaenia (OR=3.24) were independent risk factors for HDP (online supplemental table 2).

The influence of anti-dsDNA, complements and proteinuria on APOs in SLE pregnancies

The results showed that anti-dsDNA correlated slightly positively with the occurrence of foetal loss ($p = 0.147$, $p < 0.01$). The value of ds-DNA was converted into a categorical variable according to the critical cut-off value obtained with the ROC curve. Ds-DNA ≥ 14.41 IU/

Table 1 Maternal characteristics according to composite foetal adverse pregnancy outcomes (APOs)

Characteristics	Total	Composite foetal APOs		P value
		Yes (% , n=236)	No (% , n=277)	
Age \geq 35 years old	71	38 (16.1)	33 (11.9)	0.17
Primipara	238	102 (43.2)	136 (49.1)	0.18
Multiple pregnancy	8	7 (2.9)	1 (0.3)	0.03*
Prepregnancy hypertension	21	19 (8.1)	2 (0.7)	<0.01*
Diabetes	2	1 (0.4)	1 (0.3)	0.91
Remission <6 months prior to conception	18	17 (7.2)	1 (0.3)	<0.01*
Duration of SLE				
\leq 5 years	273	128 (54.2)	145 (52.3)	0.62
6–10 years	162	76 (32.2)	86 (31.0)	
>10 years	78	32 (13.6)	46 (16.6)	
Disease flares during pregnancy	145	110 (46.6)	35 (12.6)	<0.01*
APS	41	26 (11.0)	15 (5.4)	0.02*
HDP	90	69 (29.2)	21 (7.6)	<0.01*
Lupus characteristics				
<i>Mucocutaneous</i>	151	65 (27.5)	86 (31.0)	0.39
<i>Neurological disorders</i>	7	6 (2.5)	1 (0.3)	0.03*
<i>Arthritis</i>	116	53 (22.5)	63 (22.7)	0.94
<i>Serositis</i>	26	20 (8.5)	6 (2.2)	<0.01*
<i>Leukopaenia</i>	48	25 (10.6)	23 (8.3)	0.37
<i>Thrombocytopaenia</i>	42	28 (11.8)	14 (5.1)	<0.01*
<i>Renal disorders</i>	89	56 (23.7)	33 (11.9)	<0.01*
Laboratory parameters				
<i>Anti-dsDNA</i>	400	185 (78.4)	215 (77.6)	0.83
<i>Hypocomplementaemia-C3</i>	156	96 (40.7)	60 (21.7)	<0.01*
<i>Hypocomplementaemia-C4</i>	83	48 (20.3)	35 (12.6)	0.02*
<i>SSA/Ro</i>	276	129 (54.7)	147 (53.1)	0.72
<i>SSB/La</i>	70	40 (16.9)	30 (10.8)	0.04*
<i>U1RNP</i>	123	67 (28.4)	56 (20.2)	0.03*
<i>Sm</i>	35	22 (9.3)	13 (4.7)	0.04*
<i>Nucleosome</i>	131	73 (30.9)	58 (20.9)	0.01*
<i>aCL-IgG</i>	40	24 (10.1)	16 (5.8)	0.06
<i>aCL-IgM</i>	22	17 (7.2)	5 (1.8)	<0.01*
<i>β2GP1-IgG</i>	22	13 (5.5)	9 (3.2)	0.21
<i>β2GP1-IgM</i>	43	22 (9.3)	21 (7.6)	0.48
Medication				
<i>Glucocorticoid</i>	501	234 (99.2)	267 (96.4)	0.04*
<i>Hydroxychloroquine</i>	405	181 (76.7)	224 (80.9)	0.24
<i>Immunosuppressive agent</i>	45	30 (12.7)	15 (5.4)	<0.01*
<i>Aspirin</i>	398	159 (67.4)	239 (86.3)	<0.01*
<i>LMWH</i>	138	61 (25.8)	77 (27.8)	0.62

*P < 0.05.

APS, antiphospholipid antibody syndrome; HDP, hypertensive disorders of pregnancy; LMWH, low-molecular-weight heparin.

mL (AUC=0.624, YI=0.201, sensitivity=0.686, specificity=0.515) was found to be a risk factor for foetal loss among pregnant women with SLE. An AUC of less than 0.7 indicates a low diagnostic value of the optimal cut-off

value. There was no significant correlation between anti-dsDNA and other APOs ($p>0.05$).

To clarify the impact of the degree of decrease in C3 on composite foetal APOs, foetal loss and HDP, the

Table 2 Predictors of composite foetal adverse pregnancy outcomes (APOs): results of multivariable analysis

Characteristics	B	P value	OR	95% CIs
Multiple pregnancy	2.368	0.03	10.67	1.22 to 93.31
Prepregnancy hypertension	2.143	<0.01	8.52	1.81 to 40.21
Disease flares during pregnancy	1.395	<0.01	4.03	2.51 to 6.50
HDP	1.114	<0.01	3.05	1.69 to 5.47
Hypocomplementaemia-C3	0.543	0.02	1.72	1.11 to 2.67
Use of immunosuppressive agent	0.856	0.02	2.35	1.15 to 4.82

*P < 0.05.

HDP, hypertensive disorders of pregnancy.

values of C3 were set according to the interval of every 0.1 g/L decrease below the lower normal limit. Following the same method, the values of C4 were set according to the interval of every 0.01 g/L decrease below the lower normal limit (online supplemental tables 3 and 4). In addition to HDPs, we found that in both C3 and C4, the incidences of composite foetal APOs and foetal loss in any interval below the lower normal limit increased with the decrease in complement (figure 1).

A total of 140 patients (27.3%) had proteinuria before 20 weeks of gestation. The diagnostic criterion for a renal disorder in SLE is 24-hour urinary protein of >0.5 g, and proteinuria during pregnancy is defined as 24-hour urinary protein of $\geq 0.3 \text{ g}^{21}$. Therefore, all cases were divided into four groups regardless of the diagnosis: N group (n=373, without proteinuria), P1 group (n=60, $0.3 \text{ g} \leq 24 \text{ hour urinary protein} \leq 0.5 \text{ g}$), P2 group (n=46,

$0.5 \text{ g} < 24 \text{ hour urinary protein} \leq 1 \text{ g}$), and P3 group (n=34, 24-hour urinary protein >1 g).

As shown in table 5, foetal birth weights and the duration of pregnancy were highest in the N-group and lowest in the P3 group, both of which showed significant differences from each other group. Overall, the incidences of most APOs were lowest in the N group. The highest incidences of composite foetal APOs, SGA, HDP and premature birth were detected in the P3 group compared with the other three groups (p<0.05). Overall, foetal loss rates were similar in the P1, P2 and P3 groups and were higher than those in the N group (p<0.05), and premature birth rates differed significantly between each group, except for the N and P1 groups. There were no significant differences in the incidence of asphyxia neonatorum among the four groups.

Table 3 Multivariable analysis of different foetal adverse pregnancy outcomes

Characteristics	B	P value	OR	95% CI
Foetal loss				
Prepregnancy hypertension	1.739	<0.01	5.69	1.58 to 20.52
Disease flares during pregnancy	1.054	<0.01	2.87	1.45 to 5.69
Hypocomplementaemia-C3	1.552	<0.01	4.72	2.47 to 9.02
aCL-IgM positivity	1.421	0.02	4.14	1.24 to 13.84
Use of aspirin	-1.94	<0.01	0.14	0.07 to 0.29
Premature birth				
Disease flares during pregnancy	0.872	<0.01	2.39	1.48 to 3.84
HDP	0.585	0.02	1.79	1.07 to 3.00
Use of Immunosuppressive agent	0.694	0.03	2.00	1.04 to 3.86
Use of aspirin	-0.561	0.04	0.57	0.33 to 0.99
SGA				
Multiple pregnancy	2.085	<0.01	8.04	1.81 to 35.71
Disease flare during pregnancy	0.612	0.01	1.84	1.15 to 2.95
HDP	0.914	<0.01	2.49	1.49 to 4.15
Asphyxia neonatorum				
Prepregnancy hypertension	0.914	<0.01	2.49	1.49 to 0.91

HDP, hypertensive disorders of pregnancy; SGA, small for gestational age.

Table 4 Maternal characteristics according to hypertensive disorder of pregnancy (HDP)

Characteristics	Total	HDP		P value
		Yes (% <i>, n=90</i>)	No (% <i>, n=423</i>)	
Age≥35 years old	71	17 (18.9)	54 (12.8)	0.12
Primipara	238	39 (43.3)	199 (47.0)	0.52
Multiple pregnancy	8	0 (0)	8 (1.9)	0.36
History of PE	20	8 (8.9)	12 (2.8)	0.01*
Prepregnancy hypertension	21	14 (15.6)	7 (1.7)	<0.01*
Diabetes	2	0 (0)	2 (0.5)	0.51
Remission <6 months prior to conception	18	8 (8.9)	10 (2.4)	<0.01*
Duration of SLE				
≤5 years	273	48 (53.3)	225 (53.2)	0.99
6–10 years	162	28 (31.1)	134 (31.7)	
>10 years	78	14 (15.6)	64 (15.1)	
Disease flares during pregnancy	145	46 (51.1)	99 (23.4)	<0.01*
APS	41	8 (8.9)	33 (7.8)	0.73
Lupus characteristics				
<i>Mucocutaneous</i>	151	26 (28.9)	125 (29.6)	0.90
<i>Neurological disorders</i>	7	1 (1.1)	6 (1.4)	0.63
<i>Arthritis</i>	116	20 (22.2)	96 (22.7)	0.92
<i>Serositis</i>	26	10 (11.1)	16 (3.8)	<0.01*
<i>Leukopaenia</i>	48	10 (11.1)	38 (8.9)	0.52
<i>Thrombocytopaenia</i>	42	17 (18.9)	25 (5.9)	<0.01*
<i>Renal disorders</i>	89	32 (35.6)	57 (13.5)	<0.01*
Laboratory parameters				
<i>Anti-dsDNA</i>	400	73 (81.1)	327 (77.3)	0.42
<i>Hypocomplementaemia-C3</i>	156	42 (46.7)	114 (26.9)	<0.01*
<i>Hypocomplementaemia-C4</i>	83	24 (26.7)	59 (13.9)	<0.01*
<i>SSA/Ro</i>	276	42 (46.7)	234 (55.3)	0.13
<i>SSB/La</i>	70	15 (16.7)	55 (13.0)	0.35
<i>U1RNP</i>	123	24 (26.7)	99 (23.4)	0.51
<i>Sm</i>	35	6 (6.7)	29 (6.9)	0.94
<i>Nucleosome</i>	131	33 (36.7)	98 (23.2)	<0.01*
<i>aCL-IgG</i>	40	10 (11.1)	30 (7.1)	0.19
<i>aCL-IgM</i>	22	8 (8.9)	14 (3.3)	0.03*
<i>β2GP1-IgG</i>	22	2 (2.2)	20 (4.7)	0.39
<i>β2GP1-IgM</i>	43	7 (7.8)	36 (8.5)	0.82
Medication				
<i>Glucocorticoid</i>	501	90(100)	411 (97.2)	0.13
<i>Hydroxychloroquine</i>	405	67 (74.4)	338 (79.9)	0.24
<i>Immunosuppressive agent</i>	45	13 (14.4)	32 (7.6)	0.03*
<i>Aspirin</i>	398	56 (62.2)	342 (80.9)	<0.01*
<i>LMWH</i>	138	19 (21.1)	119 (28.1)	0.17

*P < 0.05.

APS, antiphospholipid antibody syndrome; HDP, hypertensive disorders of pregnancy; LMWH, low-molecular-weight heparin; PE, preeclampsia.

DISCUSSION

Our study presents a comprehensive analysis of the most important risk factors for each maternal and foetal APO in SLE pregnancy with a large sample size. We

found that prepregnancy hypertension, HDP and flares during pregnancy were key risk factors for most APOs. The ds-DNA value had a low diagnostic value for APOs, whereas the extent of complement decrease, especially




Figure 1 The incidences of adverse pregnancy outcomes (APOs) associated with the different intervals of complement C3 and C4. HDP, hypertensive disorders of pregnancy.

C3, may predict the incidence of composite foetal APOs, especially foetal loss. Proteinuria occurring in the first 20 gestational weeks may lead to APOs.

Patients with SLE have a higher incidence of APOs than the general population, including foetal loss, premature birth, SGA and HDP.^{22–27} Overall, independent risk factors for composite foetal APOs included multiple pregnancies, prepregnancy hypertension, disease flares during pregnancy, HDP, hypocomplementaemia-C3 and the use of immunosuppressive agents, similar to the conclusions of other studies.^{12 22 28} Predictors for each outcome are also proposed in this study. The main cause of foetal loss is generally recognised as aPL positivity.^{29 30} Our results showed that aCL-IgM positivity has a greater impact on foetal loss than aCL-IgG or β 2GPI positivity. In addition, hypocomplementemia-C3, prepregnancy hypertension, and disease flares during pregnancy were independent

risk factors for foetal loss, consistent with previous findings.^{9 15 24}

The main predictors of preterm birth and SGA in previous studies were lupus activity during pregnancy and HDP,^{22 31–34} which was also confirmed in our study. In addition, immunosuppressant use and disease flares were jointly found to be independent risk factors for preterm birth in the present study, indicating that they may be caused by lupus flares rather than by adverse drug events.³⁵ We still felt that immunosuppressant use should be continued in patients who benefit from therapy. Data regarding foetal complications during therapy are scarce, but no evidence of teratogenesis has emerged. In addition, many studies have ruled out the effect of multiple pregnancies on SLE pregnancy. However, the dual factors of a twin pregnancy and an abnormal placenta induced by the disease may aggravate the risk of SGA in patients

Table 5 Pregnancy outcomes of systemic lupus erythematosis (SLE) pregnancies with or without proteinuria

Characteristics	N-group (n=373, %)	P1-group (n=60, %)	P2-group (n=46, %)	P3-group (n=34, %)	P value
Live birth	348 (93.3)*	44 (73.3)	32 (69.5)	20 (58.8)	<0.01
Foetal birth weight (g, mean±SD)	2887.93±495.54*	2451.76±986.67†	2392.92±883.68†	1911.40±935.857*	<0.01
Duration of pregnancy (days, mean±SD)	254.62±34.56*	226.05±58.64†	221.87±52.84†	209.18±53.35*	<0.01
APOs					
Composite foetal APOs	134 (35.9)*	40 (66.7)†	33 (71.7)†	29 (85.3)*	<0.01
Foetal loss	26 (6.9)*	16 (26.7)	14 (30.4)	14 (41.2)	<0.01
Premature birth	83 (83/348, 23.8)‡	14 (14/44, 31.8)‡	16 (16/32, 50.0)*	15 (15/20, 75.0)*	<0.01
SGA	73 (73/348, 20.9)*	19 (19/44, 43.2)†	14 (14/32, 43.8)†	14 (14/20, 70.0)*	<0.01
Asphyxia neonatorum	6 (6/348, 1.7)	2 (2/44, 4.5)	1 (1/32, 3.1)	2 (2/20, 10.0)	0.17
HDP	31 (8.3)*	21 (35.0)†	17 (36.9)†	21 (61.7)*	<0.01

*Significantly different from each other group;

†Significantly different from the N and P3 groups;

‡Significantly different from the P2 and P3 groups;

HDP, hypertensive disorders of pregnancy; SGA, small for gestational age.

with SLE. It should be noted that for patients with SLE, multiple pregnancies caused by assisted reproductive technology should be avoided as much as possible.

In addition, our results showed that aspirin use is a protective factor for foetal loss and preterm birth, which is also consistent with other studies.^{24 36} The improved pregnancy outcome in SLE pregnancies treated with aspirin appears to correlate with the mechanism of inhibiting platelet aggregation and anti-inflammatory activity, promoting normal uterine artery flow velocity.³⁷

A total of eleven cases of asphyxia neonatorum (2.1%) were recorded in this study. In non-SLE pregnant women, hypertension increases the possibility of placental dysfunction, leading to foetal hypoxia and asphyxia after birth.³⁸ The same association for neonatal asphyxia in SLE pregnancy was found in our research.

Early studies have reported that specific predictors of HDP, especially PE complicated by SLE, include aPL positivity, thrombocytopenia, hypocomplementaemia, disease flares and renal damage.^{22 39–43} Although our results are basically consistent with those of previous studies, it is unexpected that aPL positivity and hypocomplementaemia are not independent risk factors for HDP with SLE. Our data indicate that prepregnancy hypertension, renal disorders and thrombocytopenia are more significant in predicting HDP.

Many studies have only focused on whether ds-DNA or complements are abnormal as predictors of SLE pregnancy outcomes. To clarify the degree of abnormality of these indicators that threaten SLE pregnancy outcomes, we analysed the correlation between ds-DNA, complements and APOs. We found that the value of ds-DNA correlated slightly positively with the incidence of foetal loss. In addition, we found that the incidences of composite foetal APOs and foetal loss in any interval

below the lower normal limit, whether complement C3 or C4, increased with the decrease in complements. These results may explain the clinical phenomenon that some patients with highly elevated ds-DNA did not have APOs, indicating that C3/C4 could be used as a disease severity scale rather than ds-DNA.

The diagnostic criterion for proteinuria in lupus-related renal damage is >0.5 g/d, while daily protein levels in pregnant women >0.3 g at any time during gestation is considered abnormal.⁴⁴ It was proposed that the rate of foetal loss in SLE pregnancy increases significantly when urine protein >0.5 g/day.^{45 46} In addition, Moroni *et al* reported that the odds of preterm delivery increase by 15% for each quarterly increase in proteinuria by 1 g per day.⁴⁷ However, few studies have shown the effect of proteinuria with a quantity of less than 0.5 g/24 hours or higher on SLE pregnancy outcomes. In our study, loss of 24-hour urine protein influenced the incidence of APOs. SLE pregnancies without proteinuria before 20 weeks of gestation showed the lowest incidences of foetal APOs and HDPs. Our data indicate that proteinuria (≥0.3 g/day) in the first 20 weeks of pregnancy can significantly increase the risk of foetal loss, and the premature birth rate was significantly increased when 24-hour urine protein was >0.5 g. Furthermore, the probabilities of HDP and SGA increased significantly when 24-hour urine protein was greater than 1 g, suggesting that different degrees of urine protein loss correspond to rates of different adverse outcomes in SLE pregnancy. Thus, we found that proteinuria before the 20th gestational week may be more likely to progress to HDP, similar to previous studies not focusing on the SLE population.^{48 49} Our data support the hypothesis that dividing 24-hour urine protein values during SLE pregnancy into 0.3 g, 0.5 g and 1 g can help to predict different APOs.

The findings in this study contribute to a better counselling and tailoring of obstetric surveillance in SLE pregnancy. Nevertheless, our study had some limitations. As a chart review study, inherent information bias was present. Meanwhile, there is a lack of information on uterine contraction inhibitors and follow-up frequency, which may also have an impact on pregnancy outcome. As a single-centre clinical study, it may lack external validity but also avoids the inconsistency and incomparability of data inherent in multi-centre research. Additionally, despite our large total sample size, larger sample sizes are needed to evaluate the identified predictors.

Overall, established risk factors for each APO were carefully assessed in this study. Indicators with more predictive significance have been screened out from conventional indicators, which may help clinicians predict the pregnancy outcome of patients with SLE more accurately and use more intensive monitoring approaches in SLE pregnancies to minimise the incidence of APOs.

Author affiliations

¹Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

²Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, China

³Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

⁴Shanghai Institute of Rheumatology, Shanghai, China

⁵State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Contributors Guarantor: JW and WD. Conception and design: MJ, JW and WD. Administrative support: JW and WD. Provision of study materials or patients: MJ, YC, YW, QF, JW and WD. Collection and assembly of data: MJ, YC, SL, JW, WD. Data analysis and interpretation: MJ, YC, YW, SL, JW, WD. Manuscript writing: all authors. Final approval of manuscript: all authors.

Funding This work was supported by the National Natural Science Foundation of China (Grant no. 81901494 to JY W) and by grants from the Shanghai Municipal Health Commission (Grant no. ZHYY-ZXYJHZX-202019 and GWV-10.2-YQ12 to JY W) and by grants from Shanghai "Rising Stars of Medical Talent" Youth Development Program (SHWSRS<2021>99 to JY W) and by grants from the Science and Technology Commission of Shanghai Municipality (Grant no. 18441904800 to W Di).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the ethics committee of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine (2017-113). Due to the retrospective nature of the study, informed consent was not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Qiong Fu <http://orcid.org/0000-0001-5873-6422>

Jiayue Wu <http://orcid.org/0000-0002-6247-9489>

REFERENCES

- Wang Z, Wang Y, Zhu R, *et al*. Long-Term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. *Medicine* 2015;94:e794.
- Li M, Zhang W, Leng X, *et al*. Chinese SLE treatment and research Group (CSTAR) registry: I. major clinical characteristics of Chinese patients with systemic lupus erythematosus. *Lupus* 2013;22:1192–9.
- Ko HS, Ahn HY, Jang DG, *et al*. Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. *Int J Med Sci* 2011;8:577–83.
- Whitelaw DA, Hall D, Kotze T. Pregnancy in systemic lupus erythematosus: a retrospective study from a developing community. *Clin Rheumatol* 2008;27:577–80.
- Phadungkiatwattana P, Sirivatanapa P, Tongsong T. Outcomes of pregnancies complicated by systemic lupus erythematosus (SLE). *J Med Assoc Thai* 2007;90:1981–5.
- Buyon JP, Kim MY, Guerra MM, *et al*. Predictors of pregnancy outcomes in patients with lupus: a cohort study. *Ann Intern Med* 2015;163:153–63.
- Bramham K, Hunt BJ, Bewley S, *et al*. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. *J Rheumatol* 2011;38:1906–13.
- Fischer-Betz R, Specker C. Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. *Best Pract Res Clin Rheumatol* 2017;31:397–414.
- Borella E, Lojaco A, Gatto M, *et al*. Predictors of maternal and fetal complications in SLE patients: a prospective study. *Immunol Res* 2014;60:170–6.
- Yelnik CM, Laskin CA, Porter TF, *et al*. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. *Lupus Sci Med* 2016;3:e000131.
- Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda Ángel, *et al*. Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study. *Immunol Res* 2017;65:487–94.
- Palma Dos Reis CR, Cardoso G, Carvalho C, *et al*. Prediction of adverse pregnancy outcomes in women with systemic lupus erythematosus. *Clin Rev Allergy Immunol* 2020;59:287–294.
- Chakravarty EF, Colón I, Langen ES, *et al*. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. *Am J Obstet Gynecol* 2005;192:1897–904.
- Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.
- Wu J, Zhang W-H, Ma J, *et al*. Prediction of fetal loss in Chinese pregnant patients with systemic lupus erythematosus: a retrospective cohort study. *BMJ Open* 2019;9:e023849.
- Frey HA, Klebanoff MA. The epidemiology, etiology, and costs of preterm birth. *Semin Fetal Neonatal Med* 2016;21:68–73.
- Ludvigsson JF, Lu D, Hammarström L, *et al*. Small for gestational age and risk of childhood mortality: a Swedish population study. *PLoS Med* 2018;15:e1002717.
- Berglund S, Norman M, Grunewald C, *et al*. Neonatal resuscitation after severe asphyxia—a critical evaluation of 177 Swedish cases. *Acta Paediatr* 2008;97:714–9.
- Sutton ALM, Harper LM, Tita ATN. Hypertensive disorders in pregnancy. *Obstet Gynecol Clin North Am* 2018;45:333–47.
- Ruperto N, Hanrahan LM, Alarcón GS, *et al*. International consensus for a definition of disease flare in lupus. *Lupus* 2011;20:453–62.
- Piccoli GB, Cabiddu G, Attini R, *et al*. Risk of adverse pregnancy outcomes in women with CKD. *J Am Soc Nephrol* 2015;26:2011–22.
- Chen D, Lao M, Zhang J, *et al*. Fetal and maternal outcomes of planned pregnancy in patients with systemic lupus erythematosus: a retrospective multicenter study. *J Immunol Res* 2018;2018:1–7.
- Clowse MEB. Lupus activity in pregnancy. *Rheum Dis Clin North Am* 2007;33:237–52.



- 24 Kalok A, Abdul Cader R, Indirayani I, *et al.* Pregnancy outcomes in systemic lupus erythematosus (SLE) women. *Horm Mol Biol Clin Investig* 2019;40:e31553696.
- 25 Barnabe C, Faris PD, Quan H. Canadian pregnancy outcomes in rheumatoid arthritis and systemic lupus erythematosus. *Int J Rheumatol* 2011;2011:1–6.
- 26 Baer AN, Witter FR, Petri M. Lupus and pregnancy. *Obstet Gynecol Surv* 2011;66:639–53.
- 27 Kim S-Y, Lee J-H. Prognosis of neonates in pregnant women with systemic lupus erythematosus. *Yonsei Med J* 2008;49:515.
- 28 Zhan Z, Yang Y, Zhan Y, *et al.* Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus. *PLoS One* 2017;12:e0176457.
- 29 Tian X, Li M, Ye Z, *et al.* Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE treatment and research Group registry IV. *Int J Rheum Dis* 2015;18:654–60.
- 30 Skorpen CG, Lydersen S, Gilboe I-M, *et al.* Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. *Ann Rheum Dis* 2018;77:264–9.
- 31 Jara LJ, Medina G, Cruz-Dominguez P, *et al.* Risk factors of systemic lupus erythematosus flares during pregnancy. *Immunol Res* 2014;60:184–92.
- 32 Eudy AM, Jayasundara M, Haroun T, *et al.* Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. *Lupus* 2018;27:351–6.
- 33 Liu Q, Yang H, Sun X, *et al.* Risk factors and complications of small for gestational age. *Pak J Med Sci* 2019;35:1199–203.
- 34 Liu J, Zhao Y, Song Y, *et al.* Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. *J Matern Fetal Neonatal Med* 2012;25:261–6.
- 35 Alami Z, Agier MS, Ahid S, *et al.* Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. *Therapie* 2018;73:199–207.
- 36 Salazar-Páramo M, Jara LJ, Ramos A, *et al.* Longitudinal study of antinuclear and anticardiolipin antibodies in pregnant women with systemic lupus erythematosus and antiphospholipid syndrome. *Rheumatol Int* 2002;22:142–7.
- 37 Weiner Z, Lorber M, Blumenfeld Z. Umbilical and uterine artery flow velocity waveforms in pregnant women with systemic lupus erythematosus treated with aspirin and glucocorticosteroids. *Am J Reprod Immunol* 1992;28:168–71.
- 38 Arbeille P, Perrotin F, Salihagic A, *et al.* Fetal Doppler hypoxic index for the prediction of abnormal fetal heart rate at delivery in chronic fetal distress. *Eur J Obstet Gynecol Reprod Biol* 2005;121:171–7.
- 39 Wu J, Ma J, Bao C, *et al.* Pregnancy outcomes among Chinese women with and without systemic lupus erythematosus: a retrospective cohort study. *BMJ Open* 2018;8:e020909.
- 40 Larosa M, Del Ross T, Calligaro A, *et al.* Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus. *Expert Rev Clin Immunol* 2019;15:617–27.
- 41 Lateef A, Petri M. Systemic lupus erythematosus and pregnancy. *Rheum Dis Clin North Am* 2017;43:215–26.
- 42 Mecacci F, Simeone S, Cirami CL, *et al.* Preeclampsia in pregnancies complicated by systemic lupus erythematosus (SLE) nephritis: prophylactic treatment with multidisciplinary approach are important keys to prevent adverse obstetric outcomes. *J Matern Fetal Neonatal Med* 2019;32:1292–8.
- 43 Dong Y, Yuan F, Dai Z, *et al.* Preeclampsia in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. *Clin Rheumatol* 2020;39:319–25.
- 44 Alshohaib S. Outcome of pregnancy in patients with inactive systemic lupus erythematosus and minimal proteinuria. *Saudi J Kidney Dis Transpl* 2009;20:802–5.
- 45 Wagner SJ, Craici I, Reed D, *et al.* Maternal and foetal outcomes in pregnant patients with active lupus nephritis. *Lupus* 2009;18:342–7.
- 46 Moroni G, Quagliani S, Banfi G, *et al.* Pregnancy in lupus nephritis. *Am J Kidney Dis* 2002;40:713–20.
- 47 Moroni G, Doria A, Giglio E, *et al.* Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. *J Autoimmun* 2016;74:6–12.
- 48 Morikawa M, Yamada T, Yamada T, *et al.* Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation. *J Perinat Med* 2008;36:419–24.
- 49 Chung WH, To WWK. Outcome of pregnancy with new onset proteinuria and progression to pre-eclampsia: a retrospective analysis. *Pregnancy Hypertens* 2018;12:174–7.

Supplementary Table 1. Maternal characteristics according to different foetal APOs

Characteristics	Foetal loss		P value	Premature birth		P value	SGA			Asphyxia neonatorum		P value
	Yes	No		Yes	No		Yes	No	P value	Yes	No	
	(n=70)	(n=443)		(n=128)	(n=316)		(n=120)	(n=324)		(n=11)	(n=433)	
Primipara	30	208	0.6	55	153	0.5	54	154	0.72	5	203	0.86
Multiple pregnancy	7	1	0.93	4	3	0.24	5	2	0.02*	0	7	0.91
Diabetes	0	2	0.57	1	1	0.66	0	2	0.43	0	2	0.8
Pre-pregnancy hypertension	12	9	<0.01*	8	4	<0.01*	7	5	0.29	2	10	<0.01*
Remission < 6 months prior to conception	8	10	<0.01*	8	2	<0.01*	8	2	<0.01*	1	9	<0.01*
Duration of SLE												
≤5 years	45	228	0.15	67	162	0.43	55	174	0.04*	6	223	0.42
6–10 years	16	146		42	104		49	97		3	143	
>10 years	9	69		19	50		16	53		2	67	
APS	10	31	0.04*	29	12	0.51	31	10	0.86	41	0	0.40
Lupus characteristics												
Renal disorders	22	67	<0.01*	26	41	<0.01*	28	39	0.04*	3	64	<0.01*
Mucocutaneous	22	129	0.63	33	96	0.56	31	98	0.32	2	127	0.64
Neurological disorders	3	4	0.06	1	3	0.07	3	1	0.2	0	4	0.07
Leukopaenia	9	39	0.27	13	26	0.43	9	30	0.42	1	38	0.52
Thrombocytopaenia	8	34	0.28	17	17	0.02*	15	19	0.04*	2	32	0.23
Arthritis	14	102	0.62	30	72	0.87	22	80	0.2	3	99	0.83
Serositis	13	13	<0.01*	7	6	0.03*	6	7	0.96	0	13	<0.01*

PIH = pregnancy-induced hypertension; SGA = small for gestational age; * P < 0.05

(Continued) Supplementary Table 1. Maternal characteristics according to different foetal APOs

Characteristics	Foetal loss		P value	Premature birth		P value	SGA			Asphyxia neonatorum		P value
	Yes	No		Yes	No		Yes	No	P value	Yes	No	
	(n=70)	(n=443)		(n=128)	(n=316)		(n=120)	(n=324)		(n=11)	(n=433)	
PIH	49	96	<0.01*	53	43	<0.01*	48	48	<0.01*	4	92	<0.01*
Disease flares during pregnancy	24	66	<0.01*	34	32	<0.01*	36	30	<0.01*	4	62	<0.01*
Laboratory parameters												
<i>Anti-dsDNA</i>	62	338	0.02*	93	246	0.05	88	251	0.16	8	331	0.07
<i>Hypocomplementemia-C3</i>	48	108	<0.01*	38	71	0.02*	39	70	0.56	3	106	0.26
<i>Hypocomplementaemia-C4</i>	26	57	<0.01*	18	39	0.11	19	38	0.9	1	56	0.36
<i>SSA/Ro</i>	40	236	0.45	70	166	0.69	66	170	0.76	2	234	0.04*
<i>SSB/La</i>	12	58	0.33	20	38	0.37	20	38	0.27	0	58	0.27
<i>Sm</i>	11	24	<0.01*	8	16	0.16	7	17	0.62	0	24	0.54
<i>UIRNP</i>	24	99	0.02*	33	66	0.05	34	65	0.2	1	98	0.2
<i>Nucleosome</i>	29	102	<0.01*	35	67	0.04*	31	71	0.93	2	100	0.28
<i>aCL-IgG</i>	12	28	<0.01*	10	18	0.12	10	18	0.8	0	28	0.48
<i>aCL-IgM</i>	9	13	<0.01*	7	6	0.03*	4	9	0.55	0	13	0.72
<i>β2GPI-IgG</i>	8	14	<0.01*	5	9	0.19	9	5	0.26	0	14	0.7
<i>β2GPI-IgM</i>	9	34	0.13	10	24	0.14	8	26	0.43	0	34	0.41
Medication												
<i>Glucocorticoid</i>	70	431	0.38	126	306	0.23	118	314	0.74	10	422	0.14
<i>Hydroxychloroquine</i>	41	364	<0.01*	108	257	0.08	99	266	0.27	9	356	0.29
<i>Immunosuppressive agent</i>	10	35	0.07	18	17	<0.01*	17	18	<0.01*	2	33	0.09
<i>Aspirin</i>	23	375	<0.01*	100	275	<0.01*	93	282	<0.01*	7	368	<0.01*
<i>LMWH</i>	10	128	<0.01*	39	89	0.08	35	93	0.09	0	128	0.02*

PIH = pregnancy-induced hypertension; SGA = small for gestational age; LMWH = low-molecular-weight heparin; *: P < 0.05

Supplementary Table 2. Multivariable analysis of HDP

Characteristics	B	P value	OR	95% CIs
Pre-pregnancy hypertension	2.200	<0.01	9.03	3.17–25.64
Renal disorders	0.997	<0.01	2.71	1.47–4.97
Thrombocytopaenia	1.175	<0.01	3.24	1.49–6.99

HDP = hypertensive disorders of pregnancy

Supplementary Table 3. The APOs associated with different intervals of complement-C3

Complement-C3 (g/L)	Total (N=513)	Composite foetal APOs (%)	Foetal loss (%)	HDP (%)
≥0.9	357	140 (39.2)	22 (6.1)	48 (13.4)
<0.9	156	96 (61.5)	48 (30.7)	42 (26.9)
<0.8	112	74 (66.0)	42 (37.5)	33 (29.4)
<0.7	72	55 (76.3)	36 (50.0)	25 (34.7)
<0.6	41	34 (82.9)	25 (60.9)	17 (41.4)
<0.5	27	25 (92.5)	19 (70.3)	11 (40.7)
<0.4	14	13 (92.8)	11 (78.5)	5 (35.7)
<0.3	8	7 (87.5)	6 (75.0)	3 (37.5)

Supplementary Table 4. The APOs associated with different intervals of complement-C4

Complement-C4 (g/L)	Total (N=513)	Composite foetal APOs (%)	Foetal loss (%)	HDP (%)
≥0.1	430	188 (43.7)	44 (10.2)	66 (15.3)
<0.1	83	48 (57.8)	26 (31.3)	24 (28.9)
<0.09	65	39 (60.0)	23 (35.3)	21 (32.3)
<0.08	50	33 (66.0)	21 (42.0)	18 (36.0)
<0.07	37	25 (67.5)	17 (45.9)	14 (37.8)
<0.06	22	14 (63.6)	10 (45.4)	9 (40.9)
<0.05	12	9 (75.0)	7 (58.2)	6 (50.0)
<0.04	7	6 (85.7)	5 (71.4)	4 (57.1)
<0.03	5	5 (100.0)	5 (100.0)	2 (40.0)